Current Medical Research and Opinion最新文献

{"title":"Epidemiology and approaches for management of relapsed and refractory multiple myeloma in Gulf Countries: a narrative review and insights from the Gulf multiple myeloma experts.","authors":"Ahmad Alhuraiji, Amar Lal, Amna Al Mehairi, Arif Alam, Deena Mudawi, Faraz Khan, Ibrahim Al Nabhani, Inas El-Najjar, Khalil Al-Farsi, Shabeeha K Rana, Tharwat Wagdy, Mohamed A Yassin, Paula Rodríguez Otero, Haya Haddadin, Ali Aljabban","doi":"10.1080/03007995.2025.2502125","DOIUrl":"10.1080/03007995.2025.2502125","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells, resulting in considerable morbidity and mortality. Although therapeutic advancements have improved clinical outcomes, this has been restricted to some high-income nations. Countries in the Gulf region, despite significant rises in gross domestic product (GDP), have resource-constrained environments and hence face unique challenges when it comes to the management of MM mainly because of the limited spending on healthcare (as a percentage of the GDP) in these countries. This narrative analysis explores the epidemiology, patient demographics, and therapeutic landscape of relapsed and refractory multiple myeloma (RRMM) in Gulf nations, including the United Arab Emirates (UAE), Qatar, Bahrain, Kuwait, and Oman. Our findings emphasize the growing incidence of MM in the region, with increased mortality rates owing to delayed diagnosis, restricted access to some of the advanced medicines in few areas, and disparities in care. Patients in the Gulf countries usually present at a younger age than their global counterparts, with median ages of diagnosis ranging from 43 to 58 years. Access to innovative treatments like CAR T-cell therapy and bispecific antibodies has been limited by high costs and infrastructural barriers. Stem-cell transplantation, although available in most countries, is insufficiently utilized, and treatment approaches frequently depend on conventional medicines. Obstacles to prompt diagnosis, difficulty in accessing treatment centers, limited availability of innovative treatment, and inadequate regional monitoring protocols, impede efficient illness management. Insights from the Gulf MM Advisory Board highlight the need for individualized treatment protocols, enhanced accessibility to novel treatments, and improvements in healthcare infrastructure. Cooperative initiatives among healthcare professionals, decision makers, and industry stakeholders are crucial for formulating regional treatment protocols and enhancing clinical trial networks. Reflecting on these shortcomings will be critical to improving patient outcomes and aligning MM care in the Gulf region with international standards.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"593-600"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of catheter-directed embolectomy and surgical embolectomy for intermediate- to high-risk pulmonary embolism: a retrospective observational study.","authors":"Hafiza Noor Ul Ain Baloch, Yoshiko Ishisaka, Robert Lookstein, Omar Lattouf, Madeline Ehrlich, Samuel Acquah, Jeeyune Bahk, Abdul Rehman, Janet Shapiro, David Steiger","doi":"10.1080/03007995.2025.2494639","DOIUrl":"10.1080/03007995.2025.2494639","url":null,"abstract":"<p><strong>Objective: </strong>Intermediate risk (IR)- and high risk (HR)-pulmonary embolism (PE) are associated with mortality rates that span 1.8% to 17% and greater than 31% respectively. Catheter-directed embolectomy (CDE) and surgical embolectomy (SE) for IR- and HR-PE offer alternatives to systemic thrombolysis, but data comparing CDE versus SE is limited. We assessed the outcomes of patients with acute PE who received CDE or SE for IR- and HR-PE.</p><p><strong>Methods: </strong>A retrospective review of all adult patients who had undergone CDE or SE for IR- and HR-PE in the Mount Sinai Health System between August, 2019 to June, 2022 was performed. Fisher's exact test and Student's <i>t</i>-test (or Mann-Whitney U-test) were used for comparing qualitative and quantitative outcomes respectively between the CDE and SE groups.</p><p><strong>Results: </strong>Fifteen (15) patients received SE, and 25 patients received CDE. Patients who received SE included 53% IR- and 47% HR-PE, while those who received CDE included 60% IR- and 40% HR-PE. CDE and SE had 96% and 100% technical success rates respectively. The 30-day all-cause mortality rates were 13.3% and 8% in the SE and CDE groups respectively (<i>p</i> > 0.05). The rates of major hemorrhagic complications in the CDE and SE groups were 4% and 26.7% respectively (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>CDE and SE were associated with high technical success rates in patients with IR- and HR-PE along with a low risk of major complications and acceptable 30-day all-cause mortality rates. In the absence of significant contraindications, CDE may provide a less invasive alternative to SE.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"713-720"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world cross-sectional study evaluating patient characteristics, disease burden, and treatment approaches in people with obesity disease in Japan.","authors":"Tomohiro Tanaka, Taisuke Kojima, Swathi Pathadka, Swarna Khare, Andrea Leith, Victoria Higgins, Tomotaka Shingaki","doi":"10.1080/03007995.2025.2486167","DOIUrl":"10.1080/03007995.2025.2486167","url":null,"abstract":"<p><strong>Aim: </strong>To describe clinical characteristics, disease burden, and treatment patterns among people with obesity disease (PwOD) in Japan, using data from the Adelphi Real World Obesity Disease Specific Programme™ (DSP).</p><p><strong>Methods: </strong>Secondary data from the Japanese DSP cohort (July to December 2022) were analyzed. PwOD had a BMI ≥25 kg/m² and ≥1 obesity-related complications (ORCs). Outcomes were summarized for all PwOD or stratified by obesity class (BMI ≥25-<35 or ≥35 kg/m² [high-degree obesity disease]) and use of anti-obesity medications (AOMs).</p><p><strong>Results: </strong>The study included 442 PwOD (mean age: 52.8 years; 54.8% males; BMI ≥25-<35 kg/m²: 64.5%; BMI ≥35 kg/m²: 35.5%; AOM users: <i>n</i> = 228; non-AOM users: <i>n</i> = 214). High-degree obesity disease was associated with worsened SF-36v2 scores (Physical Component Summary, Physical Functioning, Bodily Pain, and General Health), greater activity impairment, and reduced work productivity. Common weight management approaches were diet (79.9%) and exercise (51.1%). Common prescription AOMs included traditional herbal medicine (67.5%) and mazindol (21.1%). People with high-degree obesity disease (BMI ≥35 <i>vs.</i> ≥25-<35 kg/m²) used more prescription AOMs (57.3 <i>vs.</i> 48.4%), behavioral therapy (9.6 <i>vs.</i> 1.8%), and weight loss surgery (2.6 <i>vs.</i> 0.4%). The difference in weight reduction between AOM and non-AOM users was modest.</p><p><strong>Conclusions: </strong>People with high-degree obesity disease experienced greater disease burden. Diet and exercise are common for weight management, while behavioral therapy is less frequently implemented. These findings highlight the challenges and unmet medical needs in treating obesity in Japan and could inform better treatment strategies in Japan and globally among the Asian population.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"617-626"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world, observational, prospective cohort study evaluating the safety and effectiveness of CT-P13 in inflammatory bowel disease and rheumatoid arthritis: the MEGA-J study.","authors":"Tetsuya Ishida, Isamu Yokoe, Hirozumi Obata, Soyeon Park, SooKyoung Kim, Nobuaki Nishimata","doi":"10.1080/03007995.2025.2492638","DOIUrl":"10.1080/03007995.2025.2492638","url":null,"abstract":"<p><strong>Objective: </strong>The primary objective of the MEGA-J study (UMIN-CTR number: UMIN000057308) was to assess the safety of CT-P13, an infliximab biosimilar, in Japanese patients with Crohn's disease (CD), ulcerative colitis (UC), and/or rheumatoid arthritis (RA) after switching from reference infliximab.</p><p><strong>Methods: </strong>Data were collected over 5 years, following initiation of CT-P13 treatment within routine clinical practice. Interim findings are reported (cut-off: last patient's Year 2 visit). The primary endpoint was the incidence of uncommon adverse drug reactions (ADRs), including tuberculosis and serious infections.</p><p><strong>Results: </strong>Overall, 220 patients were enrolled (123 CD; 74 UC; 23 RA). Forty-eight (39.0%), 37 (50.0%), and 3 (13.0%) patients reported ≥1 uncommon ADR in the CD, UC, and RA groups, respectively. The majority (94.3%) were unrelated to CT-P13. No cases of tuberculosis and one unrelated case of serious infection were reported. Nineteen (8.6%) patients discontinued treatment for reasons related to CT-P13.</p><p><strong>Conclusions: </strong>Overall, CT-P13 was well tolerated, demonstrating the safety of long-term treatment in real-world practice.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"601-606"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of functionality, mood, and biopsychosocial status in rheumatic patients with and without self-reported bowel problems and the evaluation of BETY's impact on these factors: a retrospective study.","authors":"Nur Banu Karaca, Aysu Kahraman, Sinan Buran, Orkun Tüfekçi, Fatma Birgül Kumbaroğlu, Zeynep İrem Bulut, Senem Bulut, Aysima Barlak, Atalay Doğru, Umut Kalyoncu, Ali Akdoğan, Şule Apraş Bilgen, Sedat Kiraz, Edibe Ünal","doi":"10.1080/03007995.2025.2486164","DOIUrl":"10.1080/03007995.2025.2486164","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study aimed to evaluate the comparison of functionality, mood, and biopsychosocial status in rheumatic patients with and without self-reported bowel problems and the evaluation of <i>Bilişsel Egzersiz Terapi Yaklaşımı (BETY) - (Cognitive Exercise Therapy Approach in English)</i>'s impact on these factors.</p><p><strong>Methods: </strong>The study included 718 patients with eight different diagnoses of rheumatism. The presence of self-reported bowel problems in rheumatic patients was assessed with item 10 of the BETY-Biopsychosocial Questionnaire (BETY-BQ), functionality with the Health Assessment Questionnaire (HAQ), emotional status with the Hospital Anxiety and Depression Scale (HADS), and biopsychosocial status (BPS) with the BETY-BQ. Sixty-five rheumatic patients were included in BETY group exercise sessions for 3 months, 3 days a week.</p><p><strong>Results: </strong>The rate of self-reporting bowel problems in the total cohort was 61.6%. Among all BPS parameters examined, a significant difference was found in favor of rheumatic individuals who did not report bowel symptoms (<i>p</i> <.005). All patients included in the BETY sessions achieved improvement in all parameters, including bowel symptoms (<i>p</i> <.005).</p><p><strong>Conclusions: </strong>Many patients suffered from bowel problems. The investigated parameters of rheumatic patients with bowel symptoms were negatively affected. BETY improved all parameters, including bowel symptoms. BPS features should be considered in disease management in rheumatic patients reporting bowel problems. BETY should be used as an exercise intervention based on the BPS model in these patients.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"691-697"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world adherence to multi-target stool DNA testing for colorectal cancer screening among average risk Hispanic adults in the United States from 2016 to 2023.","authors":"Mallik Greene, Mark Camardo, A Burak Ozbay, Juliana Vanessa Rincón López, Paul Limburg, Martha Duarte","doi":"10.1080/03007995.2025.2492681","DOIUrl":"10.1080/03007995.2025.2492681","url":null,"abstract":"<p><strong>Introduction: </strong>In the United States (US), (CRC) is the second leading cause of cancer death in the Hispanic population overall. Unfortunately, the CRC screening rate in Hispanics is significantly lower than in White adults. The current study utilized real-world data to examine adherence to CRC screening with the mt-sDNA test in the Hispanic population. Additionally, sociodemographic factors that might influence patient adherence were examined to identify potential adherence barriers.</p><p><strong>Methods: </strong>This study linked two data sources: Komodo Research Data + MapEnhance Komodo Lab database and the Exact Sciences Laboratories database. Participants were Hispanic individuals aged 45-75 years who were new users of mt-sDNA testing between 2016 and 2023. Logistic regression was used to identify factors associated with adherence to mt-sDNA testing.</p><p><strong>Results: </strong>In the overall study population (<i>n</i> = 807,611), adherence to mt-sDNA testing was 64.3%. Significant variation in adherence was observed by payer type: Medicaid (53.3%), Managed Care Organization (53.4%), Medicare Advantage (62.3%), Medicare (66.5%), and commercial (66.7%) (<i>p</i> < 0.0001). Logistic regression identified additional factors that were significantly associated with greater adherence: older age, coverage by commercial insurance, residing outside metropolitan areas, prescription for CRC screening from a gastrointestinal doctor, and receiving digital outreach.</p><p><strong>Discussion: </strong>In this large, national study of combined laboratory and claims data, Hispanic individuals in the US demonstrated an overall adherence rate of 64.3%. Adherence was particularly influenced by older age, testing that was ordered by a GI specialist, and digital outreach. These data support mt-sDNA testing as a promising strategy to improve CRC screening participation among Hispanic individuals.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"579-585"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features of acquired lipodystrophy after total body irradiation: a case report and mini review.","authors":"Giuseppe Ancona","doi":"10.1080/03007995.2025.2475090","DOIUrl":"10.1080/03007995.2025.2475090","url":null,"abstract":"<p><strong>Background: </strong>Acquired partial lipodystrophy is a late complication of total body irradiation (TBI) performed during hematopoietic stem cell transplantation. Diagnosing this condition remains challenging due to its rarity and limited clinical awareness. Long-term patient observation is essential since this type of lipodystrophy develops more than a decade post-TBI.</p><p><strong>Case report: </strong>We present a unique case of a patient with acquired lipodystrophy who underwent TBI for leukemia treatment in 2003 and was diagnosed with diabetes in 2013, but standard diabetes therapies proved ineffective. By 2018, the patient exhibited distinctive features, i.e. hirsutism, reduced lean mass, cutaneous alterations (including an umbilical psoriatic plaque), barrel chest, hepatomegaly, lipoatrophy of upper and lower limbs, acanthosis nigricans in the axillae and Cushingoid facies. In 2020, she was diagnosed with breast cancer, followed by liver, ovarian and pancreatic metastases in 2021.</p><p><strong>Results: </strong>In addition to this case report, we reviewed the literature on acquired lipodystrophy cases following TBI to compare their clinical features and phenotypes with those of our patient. This comparison aims to aid clinical practice by facilitating earlier diagnosis and treatment of lipodystrophy.</p><p><strong>Conclusion: </strong>TBI can lead to acquired lipodystrophy, which is associated with severe comorbidities. Due to its diagnostic complexity, expert clinicians and a multidisciplinary approach are essential for early identification and appropriate treatment according to etiologic aspects. We hypothesize that this condition may serve as a model for studying metabolic dysfunction in fat-related diseases.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"627-637"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new paliperidone palmitate formulation: how is it different and where does it fit in our array of choices for long-acting formulations of risperidone and paliperidone?","authors":"Justin Faden, Leslie Citrome","doi":"10.1080/03007995.2025.2482654","DOIUrl":"10.1080/03007995.2025.2482654","url":null,"abstract":"<p><p>Long-acting injectable (LAI) antipsychotics have been shown to enhance treatment adherence and outcomes in individuals with schizophrenia, schizoaffective disorder, and bipolar disorder. In recent years, the U.S. Food and Drug Administration (FDA) has approved several LAIs with differing amenities of care, such as mode of administration, duration of oral medication supplementation, dosing frequency, needle gauge and size, and injection volume, amongst others. Additionally, several LAIs are distinct formulations of risperidone and paliperidone, making it difficult to distinguish between formulations, and many providers are unfamiliar with these newer agents. In 2024, a once-monthly LAI formulation of paliperidone palmitate, manufactured by Luye (PP1M Luye), was approved for the treatment of schizophrenia and schizoaffective disorder. There are similarities and differences between PP1M (Luye) and once-monthly paliperidone palmitate manufactured by Janssen (PP1M Janssen), which was FDA approved in 2009. The focus of this commentary will be to identify common characteristics and differences between these competing formulations, as well as how they relate to the overall compendium of risperidone and paliperidone LAI antipsychotic formulations.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"663-666"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic burden of myasthenia gravis in China: a nationwide registry-based study.","authors":"Jiazhou Yu, Huanyu Zhang, Shanquan Chen, Dong Dong","doi":"10.1080/03007995.2025.2475075","DOIUrl":"10.1080/03007995.2025.2475075","url":null,"abstract":"<p><strong>Background: </strong>The long-term treatment of myasthenia gravis (MG) and impaired productivity related to physical decline incur significant economic burdens on affected populations and society. This study aims to evaluate the costs of MG in China from a societal perspective and to identify the cost-driving factors.</p><p><strong>Methods: </strong>A web-based survey was conducted on 1020 MG patients recruited through a national registry system in China. Respondents reported their socio-demographic and disease-related information and annual expenses related to MG under direct medical and non-medical costs. Indirect costs were estimated among 268 working respondents based on hours of missed work and their annual income. Generalized linear models were used to identify factors associated with different categories of costs.</p><p><strong>Results: </strong>Among all respondents, the median annual direct medical cost was US$2219.0, with a median of $1860.2 contributed by medical costs and a median of $248.2 by non-medical costs. Higher education, unemployment, hospitalization, use of mechanical ventilation, and use of multiple medications were significant driving factors of direct medical and non-medical costs. Among respondents who are at least part-time employed, the indirect costs were generally minimal. Older age, physical burden of disease, and use of multiple medications were significant predictors of higher income loss.</p><p><strong>Conclusion: </strong>Population with MG in China reported heavy economic burdens related to medication. Disease severity is a major driving factor of both direct and indirect costs. Targeted policies are needed to alleviate the financial burden of MG on patients and society at large.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"487-493"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/03007995.2025.2473240","DOIUrl":"10.1080/03007995.2025.2473240","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"i"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}